253 related articles for article (PubMed ID: 15370011)
1. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
Bell J; Byron G; Gibson A; Morris A
Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
[TBL] [Abstract][Full Text] [Related]
2. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
[TBL] [Abstract][Full Text] [Related]
3. Early experience with Suboxone maintenance therapy in Hungary.
Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
[TBL] [Abstract][Full Text] [Related]
4. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
Winstock AR; Lea T; Ritter A
Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
[TBL] [Abstract][Full Text] [Related]
5. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
7. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
Bell JR; Ryan A; Mutch C; Batey R; Rea F
Drug Alcohol Depend; 2008 Jul; 96(1-2):183-6. PubMed ID: 18423901
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA; Bickel WK; Badger GJ; Jacobs EA
Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
13. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
Alho H; Sinclair D; Vuori E; Holopainen A
Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
15. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).
Welsh C; Sherman SG; Tobin KE
Addiction; 2008 Jul; 103(7):1226-8. PubMed ID: 18554353
[TBL] [Abstract][Full Text] [Related]
16. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
[TBL] [Abstract][Full Text] [Related]
17. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.
Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R
Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685
[TBL] [Abstract][Full Text] [Related]
20. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
